systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-187Research ArticleСТАТЬИARTICLESРамиприл - ингибитор ангиотензинпревращающего фермента с широким спектром терапевтического действияRamipril - angiotensin converting enzyme ingibitor with a wide spectrum of therapeutic actionПреображенский,Д. В.noemail@neicon.ruВышинскаяИ. Д.noemail@neicon.ruPreobrazhenskyD. V.noemail@neicon.ruVyshinskajaI. D.noemail@neicon.ruГОУ ВПО Московская медицинская академия им. И.М.СеченоваRussian Federation200923122022611722Copyright © Преображенский, Д.В., Вышинская И.Д., Preobrazhensky D.V., Vyshinskaja I.D., 20222022Преображенский, Д.В., Вышинская И.Д., Preobrazhensky D.V., Vyshinskaja I.D.Преображенский, Д.В., Вышинская И.Д., Preobrazhensky D.V., Vyshinskaja I.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/187артериальная гипертензияИАПФрамиприлarterial hypertensionACE inhibitorsramiprilReferencesСидоренко Б.А., Преображенский Д.В. Клиническое применение ингибиторов ангиотензин-превращающего фермента. М.: ЛИА "Пресид", 1998.Сидоренко Б.А., Преображенский Д.В. Клиническое применение ингибиторов ангиотензин-превращающего фермента. М.: ЛИА "Пресид", 1998.Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензинпревращающего фермента. М.: ЗАО "Информатик", 1999.Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензинпревращающего фермента. М.: ЗАО "Информатик", 1999.Opie LH. Angiotensin converting enzyme inhibitors. 2 ed N.Y.: Wiley-Liss, 1994.Opie LH. Angiotensin converting enzyme inhibitors. 2 ed N.Y.: Wiley-Liss, 1994.Opie LH. Angiotensin converting enzyme inhibitors. 3 ed N.Y.: Wiley-Liss, 1999.Opie LH. Angiotensin converting enzyme inhibitors. 3 ed N.Y.: Wiley-Liss, 1999.Opie LH. Drugs for the heart. 4th ed Philadelphia, 1995.Opie LH. Drugs for the heart. 4th ed Philadelphia, 1995.Gohlke P, Unger T. Ramipril Cardiovascular drug therapy. Ed. F. Messerli 2th ed Philadelphia, 1996: 755-75.Gohlke P, Unger T. Ramipril Cardiovascular drug therapy. Ed. F. Messerli 2th ed Philadelphia, 1996: 755-75.Ball SG, Roberson JIS. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59: 23D-7D.Ball SG, Roberson JIS. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59: 23D-7D.Todd PA, Benfield P. Ramipril: a review of its pharmacologic properties and therapeutic efficacy in cardiovascular disoreders. Drugs, 1990; 39: 110-35.Todd PA, Benfield P. Ramipril: a review of its pharmacologic properties and therapeutic efficacy in cardiovascular disoreders. Drugs, 1990; 39: 110-35.Smith WHT, Ball SG. Ramipril. Int. J. Clin. Practice, 2000; 54: 255-60.Smith WHT, Ball SG. Ramipril. Int. J. Clin. Practice, 2000; 54: 255-60.Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А. Ингибиторы ангиотензин-превращающего фермента - М.: Литтерра, 2007.Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А. Ингибиторы ангиотензин-превращающего фермента - М.: Литтерра, 2007.Ивлева А.Я. Клиническое применение ингибиторов ангиотензинпревращающего фермента и антагонистов ангиотензина II. М.: Миклош, 1998.Ивлева А.Я. Клиническое применение ингибиторов ангиотензинпревращающего фермента и антагонистов ангиотензина II. М.: Миклош, 1998.Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. ИАПФ и АТ1-ангиотензиновые блокаторы в клинической практике. Часть вторая. М.: ЗАО "Презид-Альянс", 2004.Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. ИАПФ и АТ1-ангиотензиновые блокаторы в клинической практике. Часть вторая. М.: ЗАО "Презид-Альянс", 2004.Zannad F, Matzinger A, Larche J. Trough/peak rations of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertension 1996; 9: 633-43.Zannad F, Matzinger A, Larche J. Trough/peak rations of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertension 1996; 9: 633-43.Eichstadt HW, Felix R, Langer M et al. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am J Cardiol 1987; 59: 98D-103D.Eichstadt HW, Felix R, Langer M et al. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am J Cardiol 1987; 59: 98D-103D.Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertension 1995; 13: 1225-334.Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertension 1995; 13: 1225-334.Psaty B, Smith NL, Siscovick DS et al Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic review and meta-analysis. JAMA 1997; 277: 739-45.Psaty B, Smith NL, Siscovick DS et al Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic review and meta-analysis. JAMA 1997; 277: 739-45.Pahor M, Psaty BM, Alderman MA et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54.Pahor M, Psaty BM, Alderman MA et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regims on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-35.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regims on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-35.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000; 342: 145-53.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000; 342: 145-53.The Acute Infarction Ramipril Efficacy (AIRE) study investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1994; 342: 821-8.The Acute Infarction Ramipril Efficacy (AIRE) study investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1994; 342: 821-8.Hall AS, Murray GD, Ball SG et al. Follow-up study of patients randomly allocated ramipril of placebo foe heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Lancet 1999; 349: 1493-7.Hall AS, Murray GD, Ball SG et al. Follow-up study of patients randomly allocated ramipril of placebo foe heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Lancet 1999; 349: 1493-7.The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.Ruggenenti P, Perna A, Gherardi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.Ruggenenti P, Perna A, Gherardi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
The authors declare that there are no conflicts of interest present.